How India Exports Empagliflozin to the World

Empagliflozin, marketed under the brand name Jardiance, received FDA approval in August 2014 for the treatment of type 2 diabetes mellitus. As of March 2026, the FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for empagliflozin, indicating the presence of generic versions in the U.S. market. The approval of these generics has intensified competition, potentially impacting the market share of Indian exporters. Notably, Boehringer Ingelheim India Private Limited, a significant exporter with a 10.2% share, may face challenges due to this increased competition.

The FDA has not issued any import alerts specific to empagliflozin as of March 2026. However, Indian exporters must adhere to stringent FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and successful completion of the ANDA process, to ensure market access. The presence of 170 active Indian exporters underscores the competitive landscape and the necessity for strict regulatory compliance.

The European Medicines Agency (EMA) granted marketing authorization for Jardiance (empagliflozin) in May 2014. In November 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending an extension of the indication to include treatment of chronic kidney disease. This expansion reflects the evolving therapeutic applications of empagliflozin. (ema.europa.eu)

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) continues to align with EMA decisions post-Brexit, ensuring that empagliflozin remains authorized for use. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for Indian exporters targeting these markets. The significant export volumes to Belgium (12.1%) and the UK necessitate adherence to these stringent regulatory requirements.

Empagliflozin is included in the 22nd edition of the WHO Model List of Essential Medicines, published in 2021, highlighting its importance in managing type 2 diabetes mellitus. While empagliflozin is not currently listed under the WHO Prequalification Programme, compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is crucial for Indian exporters to meet global quality expectations.

In India, empagliflozin is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on empagliflozin as of March 2026, allowing market-driven pricing. For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations.

The primary patent for empagliflozin expired in August 2024, leading to the entry of generic competitors into the market. This development has intensified competition among the 170 active Indian exporters, potentially affecting profit margins and market dynamics.

In June 2025, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) identified non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect of GLP-1 receptor agonists, including empagliflozin-containing products. This finding necessitates updated safety information and increased vigilance among healthcare providers. (ema.europa.eu)

In July 2025, the EMA's CHMP adopted a positive opinion recommending the extension of the indication for Invokana (canagliflozin) to include treatment of children aged 10 years and older with type 2 diabetes mellitus. This decision reflects a broader trend of expanding indications for SGLT2 inhibitors, potentially influencing the market dynamics for empagliflozin. (ema.europa.eu)

In November 2023, the EMA's CHMP adopted a positive opinion recommending an extension of the indication for Jardiance (empagliflozin) to include treatment of chronic kidney disease. This expansion underscores the evolving therapeutic applications of empagliflozin and may impact its market demand. (ema.europa.eu)

In August 2025, the FDA approved a new combination therapy involving empagliflozin and metformin for the treatment of type 2 diabetes mellitus. This approval introduces additional competition in the market, affecting Indian exporters.

In December 2025, the NPPA conducted a review of anti-diabetic drug prices, including empagliflozin, to assess market trends and ensure affordability. While no immediate price controls were implemented, the review indicates potential regulatory interventions that could impact pricing strategies for Indian exporters.

Empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor used in the management of type 2 diabetes, is primarily manufactured in India. However, the production of its active pharmaceutical ingredient (API) often relies on key starting materials (KSMs) sourced from China. This dependency exposes the supply chain to potential disruptions stemming from regulatory changes, environmental policies, or geopolitical tensions affecting Chinese manufacturing facilities. For instance, in February 2019, reports indicated that over 140 API manufacturers in the Beijing-Tianjin-Hebei region ceased operations due to stringent environmental regulations, leading to global supply chain disturbances.

The COVID-19 pandemic further highlighted vulnerabilities in the pharmaceutical supply chain. In 2020, the U.S. Food and Drug Administration (FDA) issued a complete response letter for empagliflozin 2.5 mg, citing concerns related to manufacturing facilities. Such events underscore the risks associated with over-reliance on specific regions for critical raw materials and APIs.

Analysis of TransData Nexus's proprietary trade data from 2022 to 2026 reveals that the top five Indian exporters of empagliflozin account for 45.3% of total exports, with LAWRENCE WALTER leading at a 12.7% share. This concentration indicates a moderate risk of supply disruption if any of these key suppliers face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API production and reduce dependency on imports. This initiative is expected to diversify the supplier base and enhance the resilience of the pharmaceutical supply chain.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceuticals. Any geopolitical tensions or conflicts in these regions can lead to delays and increased costs. Additionally, ongoing U.S.-China trade tensions have the potential to disrupt the supply of KSMs and APIs, further impacting the availability of empagliflozin.

While there have been no specific FDA or European Medicines Agency (EMA) shortage alerts for empagliflozin as of March 2026, the broader pharmaceutical industry has experienced shortages of similar medications. For example, in October 2024, the FDA addressed shortages of GLP-1 receptor agonists, emphasizing the importance of proactive supply chain management.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to strengthen local manufacturing capabilities for APIs and KSMs.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could impact supply chains, enabling proactive risk management.

• Develop Contingency Plans: Create and regularly update comprehensive contingency plans to address potential supply disruptions, including alternative shipping routes and emergency stockpiles.

• Strengthen Regulatory Compliance: Ensure all manufacturing facilities adhere to international quality standards to prevent regulatory actions that could disrupt supply.

RISK_LEVEL: MEDIUM